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ABSTRACT
Objectives: We investigated health professionals with a solid
background in health-care management and economics to
get their opinion and attitude on the use of economic evalu-
ation at the policy, organizational, and professional levels of
decision-making.
Methods: A 12-item questionnaire was sent to 374 Italian
health-care professionals who received training in economic
evaluation of health-care programs in the last 10 years at the
Bocconi School of Management, Milan, Italy.
Results: The response rate was 46.8% (175 questionnaires).
All respondents stated that the basics of economic evaluation
analysis must be part of the overall knowledge of health-care
professionals. The usefulness of economic evaluation for pro-
fessional activities was rated 3.83 (scale 1–5). Respondents
stated that economic evaluation is used more for managerial
decisions than for clinical ones (mean 2.89 vs. 2.74,
P = 0.09). “Decisions are taken according to a short-term
perspective” was the most frequently reported barrier for the
actual use of economic evaluation studies, particularly by
managers (76.7%). “More training in health economics”
was indicated as the incentive to expand its use by the major-
ity of both clinicians and managers (64.6%). Signiﬁcantly
more managers than clinicians (74.4% vs. 54.1%, P = 0.005)
considered that the maximum beneﬁts of economic evalua-
tion are reaped at organizational level.
Conclusions: Informed Italian health professionals have a
positive attitude toward the principles and the techniques of
economic evaluation. They show appreciation of their poten-
tial role and report making some use of them in actual deci-
sion making.
Keywords: decision making, economic evaluation, health-
care management, Italy.
Introduction
Economic evaluation of health-care programs has a
unique position in socioeconomic research. We are not
aware of any other applied social science discipline so
proliﬁc; each year thousands of empirical articles are
published in medical and other health-care journals,
and several electronic databases make them accessible
to  decision-makers.  Parallel  to  the  massive  increase
in the production of studies, relevant advances have
occurred in methods development. Major health eco-
nomics journals regularly publish articles on method-
ological issues such as productivity costs, discounting,
and sensitivity analysis. Despite various methodologi-
cal issues still being debated, economic evaluation
scholars form an active scientiﬁc community with a
shared standard on methods and techniques and a
common language. In addition, in many countries,
government institutions seem to appreciate the contri-
bution of economic evaluation because they ofﬁcially
recognize its potential role in decision making, man-
date the production of studies for reimbursement and
pricing of new technologies (mainly drugs), and
endorse guidelines on how to perform appropriate
studies [1]. Indeed, this young discipline seems to pro-
vide a rare example of knowledge production consist-
ent with societal needs, with a large and growing
research community serving health-care systems in
need of economic evidence to improve the allocation of
scarce resources. But is the story really so nice?
The large number of empirical studies contrasts
with the paucity of research on their impact on deci-
sion making [2] and the few studies available suggest
that their use in decision processes is modest [3–6].
Nevertheless, even to answer the question “Do eco-
nomic evaluation studies inﬂuence decision making?”
is not as easy as it appears. A recently published pilot
study emphasized that outcomes in terms of cost-effec-
tiveness ratio may not capture all relevant information
in a way that policymakers can relate to [7]. Decision
making is a complicated intellectual process whose
ingredients (information, problems, search and learn-
ing mechanisms, selection rules) is interrelated and
result in different decision strategies [8]. Consequently,
it seems important to acknowledge that decision mak-
ing is a very complex endeavor, that there are a variety
of decisions taken at different levels of the system, and
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that decision-makers play various roles relating to dif-
ferent informational requirements, different objectives,
and different budgetary responsibilities [7].
Despite unrealistic models still taught in some eco-
nomic courses, public resources are not allocated by a
visible hand (e.g., the Department of Health) interpret-
ing a societal point of view. Consumption of govern-
ment resources are decided at different levels by
policymakers, managers, and professionals with vari-
ous degrees of autonomy and performing different
activities that are coordinated only to a limited extent.
The use of economic evaluation studies has been
investigated in the United States and in some European
countries. We focus here on European studies because
the US evidence appears difﬁcult to generalize about,
given the peculiarities of its health-care system. The
only multinational European study we are aware of
was carried out in 1998 and involved nine countries
(Euromet survey) [4]. Various types of decision-makers
were surveyed through postal questionnaires (968
respondents), semistructured interviews and focus
groups (73 individuals). In the sample, the extent of
knowledge about health economics appeared limited.
On average, one-third of respondents reported they
had received some training in health economics. In all
countries, surveyed individuals reported that economic
considerations were important and that they had to be
used in decision-making. They also stated that the use
of economic studies in decision processes had been
modest,  mainly  because  of  institutional  factors  such
as difﬁculties in moving resources from one sector
(budget) to another, tightness of budgets, and the vir-
tual nature of savings predicted by studies. The major-
ity of respondents to this European survey reported
that sponsorship of studies might bias results and
generate a lack of credibility of economic evaluation
studies.
Results of this survey appear consistent with two
studies performed in the UK. Drummond and col-
leagues [3] surveyed medical and pharmaceutical
advisers (those who advise general practitioners [GPs]
on prescribing), hospital directors of pharmacy, and
directors of public health. According to this postal sur-
vey, important obstacles to the use of economic eval-
uation were that resources cannot be moved from
secondary to primary care, studies funded by the
industry are not credible, they are biased because of a
large number of assumptions, and because budgets are
so tight that no resources are available to adopt new
therapies. In a qualitative research involving various
types of decision-makers at the local level, Duthie et al.
concluded that different individuals seek different out-
comes, that health economics needs to produce action-
able results, and that any cost saving must be
applicable to be relevant for decision-making [6].
Interestingly, the authors stated that health economists
are perceived to be ill informed about the way the Brit-
ish National Health Service (NHS) works; they tend to
produce evidence that reﬂects the burden to the society
as a whole, although real-world decision-makers oper-
ate within speciﬁc ﬁnancial constraints. In a more
recent UK study, most participants felt that the value
of studies is often limited because of the poor general
applicability of results and the narrowness of the
research question [9]. Moreover, they would have liked
more assurance about the methodological rigor of
studies because their knowledge of health-economic
concepts and methodology was often limited.
Attitude toward economic evaluation studies on
pharmaceuticals at organizational and professional
levels was also investigated by a Swedish survey
administered to 312 members of central formulary
committees [10]. Respondents expressed a positive
attitude about using pharmacoeconomic studies. They
expressed interest in the contribution of economic
evaluation but said they had neither the competence
nor the relevant studies to work with. The majority of
respondents identiﬁed the translation of studies into
actionable results and a lack of comparability among
studies as the main obstacles to the use of pharmac-
oeconomic evaluations. In contrast with the UK stud-
ies, this survey shows there is a positive attitude about
economic evaluation in a broad sense (e.g., adopting a
societal perspective) and underlies the role of health
economics experts as “brokers” of economic evalua-
tion studies. Nevertheless, it is important to remark
that respondents were members of pharmaceutical for-
mulary committees without ﬁnancial responsibility
related to drugs, and thus were more prone to adopt a
societal perspective in decision-making.
The Swedish results are partly in contrast with
those of a qualitative research conducted in a region of
France [5]. Interviews of pharmacists who were mem-
bers of formulary committees of a stratiﬁed sample of
hospitals revealed that the inﬂuence of economic data
on the determination of the formulary list was limited
and that pharmacoeconomic evaluations were rarely
used. Based on these results the authors concluded that
the use of economic evaluation may be overstated by
the literature and that “in order to increase the use of
economic data, it is ﬁrst necessary to create an envi-
ronment that is more favorable to its application” [5].
We are aware of only two recent empirical studies on
the attitude of decision-makers toward economic eval-
uation in Italy. Tarricone [11] has surveyed 321 gen-
eral managers of Italian Health Authorities, Hospital
Trusts, and regional Ministries of Health to investigate
their knowledge of and attitude toward economic eval-
uation. Results suggest a general awareness of the role
of economic valuation. Eighty-ﬁve percent of general
managers stated that economic evaluation is an impor-
tant contribution to decision-making. Interestingly,
general managers of Health Authorities and Hospital
Trusts appeared to have a better knowledge of and a
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more positive attitude toward economic evaluation
than directors of the regional Ministries of Health. The
second study was conducted on a convenient sample of
34 public managers and physicians working for the
NHS [12]. It shows that decision-makers attribute
more importance to clinical data than to cost data in
economic evaluation studies, that they rely on scientiﬁc
publications as the main source of economic evidence,
and that they are generally skeptical about studies
sponsored by pharmaceutical companies. Overall, they
perceive that economic evaluation has a moderate
impact on the reimbursement status of pharmaceuti-
cals and in the deﬁnition of hospital formularies, and
that it will assume more importance in the future.
This short review of the literature on the use of eco-
nomic evaluation at organizational and professional
levels in Europe does not suggest bold statements. It
seems that decision-makers are increasingly aware that
resources are scarce and that economic evaluation
might provide a valid aid. Nevertheless, the available
evidence also suggests that economic studies are rarely
used and that various obstacles make economic eval-
uation research little actionable, even though their
main objective is to offer guidance to decision-makers.
Obviously, the lack of impact of economic evaluations
is a serious threat for the discipline, and serious
research investigating this issue is urgently needed.
Nevertheless, we think that the empirical research we
have reviewed has oversimpliﬁed the issue, assuming a
simple and linear relationship between research and
decision-making. Furthermore, none of these studies
has investigated whether different roles in the health-
care system may inﬂuence the attitude of decision mak-
ers toward economic evaluation. For example, it is
generally assumed that clinicians and managers have
different perspectives about the use of economic crite-
ria to make decisions, but empirical studies have not
focused on this issue.
The main objective of this article is to widen the dis-
cussion on the use of economic analysis so to take into
consideration the plurality of decision-making levels
and actors. More precisely, we want to get information
about the perception and the attitude of professionals
about the role of economic evaluation at different deci-
sion-making level. In addition, we want to test whether
different organizational roles results in different per-
ceptions and attitudes toward economic evaluation.
Methods
The sample was drawn from participants of a Health
Care Management Executive program (Corgesan)
delivered yearly at Bocconi School of Management in
Milan. Corgesan is a 10-month program designed for
medical doctors. Participants come from all the Italian
regions and attend classes for nine sessions of four
consecutive full days each. The contents of the pro-
gram focus on health management issues, although
major elements of heath economics can be found in
various courses. A special section toward the end of
the program (one and a half days of teaching) focuses
on economic evaluation of health-care programs; its
content includes a short description of the main tech-
niques, one or two short case discussions, and an exer-
cise on incremental cost-effectiveness analysis.
Although the content and the reading material for this
“section” have been regularly updated over time, the
basic structure and the main instructor have not
changed in the last 10 years.
The choice of this study population was motivated
by two main reasons. First, we wanted to make sure
that all the surveyed individuals had some previous
knowledge about economic evaluation principles and
techniques. Previous studies have suggested that results
may be signiﬁcantly inﬂuenced by a misperception of
what constitutes economic evaluation [4]. Second, this
was a national convenience sample of medical doctors
(around 95% of all participants are medical doctors)
who had invested a signiﬁcant amount of time and
money in acquiring management skills, and, for most
of them, to pursue a professional career in health-care
management. This convenient sample allowed us to
gather information from “informed” people who
make an emerging professional group.
Postal questionnaires were sent to all alumni who
had completed the program in the last 10 years.
Addresses were drawn from the School database gen-
erated at the time of enrollment, which is voluntarily
updated by participants. A total of 374 questionnaires
were mailed in March 2004. We sent a packet with the
questionnaire and a letter explaining the purpose of
the study. To facilitate the return of the completed
questionnaire, a prestamped, addressed envelope was
also included in each packet. Before mailing, a focus-
group meeting with ﬁve alumni of the program served
as a pilot to improve validity and reliability. As a result
of the pilot, two questions designed to detect the objec-
tive knowledge about economic evaluation techniques
(calculating incremental cost-effectiveness ratios and
using threshold values) were removed from the ﬁnal
version of the questionnaire and various questions
were reworded. Approximately three weeks after the
mailing, questionnaire recipients were telephoned to
verify whether the questionnaire reached its destina-
tion and to stimulate nonresponders.
The ﬁrst part of the questionnaire focused on socio-
demographic characteristics of survey participants
(age, sex, type of health-care organization, and
region). Furthermore, the participants were asked to
state their organizational roles and type of activities
mainly performed (clinical, managerial or a mix of the
two). The second part of the questionnaire contained
12 questions, out of which 11 were multiple choice
and the last asked for qualitative comments
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(Appendix). The questions were organized in four
blocks.
The ﬁrst block investigated whether survey partici-
pants perceived training and knowledge diffusion of
health economics among health-care professionals use-
ful, according to a scale from 1 to 5 where 1 repre-
sented “not useful at all” and 5 “very useful.”
The second block of questions was designed to eval-
uate to what extent the methods of economic evalua-
tions are actually used in health-care organizations for
clinical and managerial decision-making, according to
a scale from 1 to 5 where 1 corresponded to “not used
at all” and 5 to “very much used.” Multiple choice
questions were used in the third block and aimed at
assessing the major barriers for—and the elements that
could facilitate a wider use of—economic evaluations
in health care. Survey participants were asked also to
provide their opinion regarding the content and the
level of decision making for which the economic eval-
uations could contribute the most in supporting deci-
sion makers.
The last part of the questionnaire was designed to
assess the respondents’ perceived knowledge about
economic evaluation. More speciﬁcally, respondents
were asked to self-evaluate their knowledge of eco-
nomic evaluation techniques on a scale from 1 to 5 and
to report how many times they have analyzed studies
in the last year.
Data were analyzed using the statistical program
package STATA 8.2 (StataCorp, College Station, TX,
USA). The overall sample was divided in two groups:
those who mostly perform managerial activities were
labeled as “managers” and those who mainly perform
clinical activities were labeled as “clinicians.” Among
those who answered “mix of the two,” the attribution
to each of the two groups was made according to their
organizational role. Those who headed departments or
large organizational units were considered as manag-
ers whereas those who did not report they held such
posts were labeled as clinicians.
For each question, analysis was conducted on the
overall sample and for the two professional proﬁles
separately. The differences between the groups were
analyzed by appropriate statistical tests: Mann–
Whitney U-test for the comparison of ranks and chi-
squared test for the comparison of proportions in two
groups. In each case, the null hypothesis was that there
was no difference between the two groups. This was
tested against two-sided alternatives.
Results
Of the 374 questionnaires sent out, 175 (46.8%) were
returned completed and all these were included in the
present analysis. Respondents slightly over represented
participants of most recent editions of the training pro-
gram, living in the northern regions and in 40 to 50
age bracket (Table 1). Concerning their professional
proﬁle, 48.6% (85) of respondents were classiﬁed as
“clinicians” and the rest were labeled as “managers.”
The two groups were not signiﬁcantly different with
respect to sociodemographic variables considered (age,
geographic area, and year of course attendance).
All 175 survey participants agreed that the basics of
economic evaluation analysis should be a mandatory
part of the overall training of professionals working in
the health-care ﬁeld. None of the respondents rated the
economic evaluation as not useful at all. The useful-
ness of  economic  evaluation  was  assessed  according
to two perspectives (Table 2). The ﬁrst perspective
Table 1 Survey respondents and target sample characteristics
Survey respondents
Target sample 
(N = 374) Total (N = 175)
By type of activity
Clinicians
(N = 85)
Managers
(N = 90)
N % N % N % N %
Sex
Male 123 70.3 60 70.6 63 70.0 259 69.3
Female 52 29.7 25 29.4 27 30.0 115 30.7
Age (year)
30–39 9 5.1 5 5.9 4 4.4 28 7.5
40–59 112 64.0 55 64.7 57 63.3 188 50.1
50–60 54 30.9 25 29.4 29 32.2 158 42.3
Geographical area
Northwest 69 39.7 31 36.5 38 42.2 144 38.5
Northeast 29 16.7 20 23.5 9 10.0 34 9.2
Center 36 20.7 19 22.4 17 18.9 87 23.2
South and islands 40 23.0 15 17.7 26 28.9 109 29.1
Year of attendance
1993–96 31 17.7 10 12.2 20 22.7 108 28.8
1997–2000 77 44.1 37 45.1 38 43.2 183 49.1
2001–04 67 38.2 35 42.7 30 34.1 83 22.1
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focused on assessing the usefulness of economic eval-
uation for performing professional activities. The
mean rate was 3.83 (SD 0.83; range 2–5). Managers’
ratings were higher than those of clinicians: economic
evaluations were considered very useful by 30.0% of
managers and by 12.9% of clinicians (chi-square test,
P < 0.01). In the second perspective, the focus was on
the value of economic evaluation as a cultural and log-
ical framework, without explicit reference to its pro-
fessional relevance. In this case, the usefulness of
economic evaluation was deemed even more impor-
tant: respondents rated the value of economic evalua-
tion at 4.19 (SD 0.72, range 2–5).
The actual use of economic evaluation studies in
decision processes conducted in responders’ own
working environment was assessed separately for two
types of decisions: clinical and managerial. On aver-
age, respondents thought that economic evaluation is
used more for managerial decisions (e.g., launch of a
prevention program) than for clinical ones (choice of
drug therapies) (mean 2.89 vs. 2.74, P = 0.09). This
opinion was stronger among managers: in this group,
the use of economic evaluation for managerial deci-
sions was reported to be signiﬁcantly higher than for
clinical decisions (3.07 vs. 2.69, P < 0.05). A variety of
factors was considered responsible for limiting the use
of economic evaluation (Table 3). The most frequently
reported barrier (69.7% of respondents) was the focus
on short-term perspectives of decision-making (i.e.,
long-term costs and consequences are not adequately
taken into account). Signiﬁcantly more managers than
clinicians considered this factor limiting (76.7% vs.
62.4%, P = 0.04). Conversely, “Lack of knowledge of
decision-makers” was found important by signiﬁcantly
more clinicians than managers (54.1% vs. 33.3%,
P < 0.01). The item “Studies are not credible since they
are conducted/sponsored by nonindependent parties”
was not perceived as a major barrier (10.3%). “More
training in health economics,” and “Guidelines to
increase comparability of studies” were the interven-
tion for facilitating the use of economic evaluation
most frequently reported (Table 3). Conversely, “Eas-
ier access to studies” was reported by only 20% of the
respondents.
The main clinical areas for which economic evalu-
ation analysis could provide most beneﬁts in real-life
decision making were “Drugs,” “Prevention,” and
“Diagnostic Services” (Fig. 1).
Sixty-ﬁve percent of the respondents stated that
major beneﬁts from economic evaluation studies are
Table 2 Importance, use, and knowledge of economic evaluation studies—mean (median)
All respondents
(N = 175)
Clinicians
(N = 85)
Managers
(N = 90) P-value*
Importance and usefulness of health economics
knowledge/training
At professional level 3.83 (4) 3.72 (4) 3.94 (4) 0.059
As a cultural framework 4.19 (4) 4.13 (4) 4.24 (4) 0.227
Actual use of economic evaluation in decision-making
For clinical decisions 2.75 (3) 2.63 (3) 2.86 (3) 0.143
For managerial decisions 2.89 (3) 2.69 (3) 3.07 (3) 0.024
Perceived extent of knowledge in economic evaluations 2.80 (3) 2.78 (3) 2.82 (3) 0.844
*Mann-Whitney U-test.
Table 3 Main barriers to and possible facilitating factors for a wider use of economic evaluation studies
All respondents
(N = 175)
Clinicians
(N = 85)
Managers
(N = 90) 
P-value*N % N % N %
Barriers
Decisions taken in short-term perspective 122 69.7 53 62.4 69 76.7 0.039
Excessive focus on expenditure control 87 49.7 44 51.8 43 47.8 0.598
Lack of knowledge by decision-makers 76 43.4 46 54.1 30 33.3 0.006
Difﬁculty of moving resources between sectors 72 41.1 36 42.4 36 40.0 0.752
Lack of incentives for economically rational choices 71 40.6 35 41.2 36 40.0 0.874
Limited timely access 29 16.6 13 15.3 16 17.8 0.659
Studies are not reliable because of sponsorship 18 10.3 10 11.8 8 8.9 0.531
Facilitating factors
More training in health economics 113 64.6 57 67.1 56 62.2 0.504
Establishing guidelines 107 61.1 50 58.8 57 63.3 0.541
Support services to decision-makers 94 53.7 49 57.6 45 50.0 0.311
More ﬂexibility in resource allocation 92 52.6 42 49.4 50 55.6 0.416
Easier access to studies 35 20.0 19 22.4 16 17.8 0.450
*Chi-squared test.
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reaped by using it at organizational level (Fig. 2). This
perception is signiﬁcantly more frequent among man-
agers (74.4%) than clinicians (54.1%, P < 0.01). Nev-
ertheless, the ranking of different decision levels was
the same for the two groups. Only 13.1% of all
respondents stated that economic evaluation could
provide major beneﬁts when used at a clinical level
(16.7% of managers and 9.4% of clinicians,
P = 0.156).
According to a 1 to 5 scale, the overall mean of per-
ceived knowledge of economic evaluation was 2.79
(SD 0.77, range 1–5) and it was similar in the two
groups (Table 2). Most of the respondents (52.9%)
indicated that they consulted economic studies from
one to three times in the last year (Fig. 3). Managers
tended to read economic studies more often than cli-
nicians (27.8% of managers said that they had read at
least three studies in the last year vs. 16.7% of clini-
cians, P = 0.08). 
Discussion
To make sense of our survey it is important to clarify
the main characteristics of the respondents. Our con-
venience sample is different from those of previous
surveys on this topic. First, it is made up almost
exclusively of Italian medical doctors although the pre-
vious European studies investigated decision-makers
with various professional backgrounds (hospital phar-
macists [3–6,10], sickness funds, and governmental
agencies employees [4], GPs [6], medical and pharma-
ceutical advisers [3,6]). Second, they are a special cat-
egory of medical doctor because the decision to invest
money and time for training in health management
make them a sample of individuals who are likely to be
very interested in policy and management issues. In the
Euromet study, only one-third of respondents had
undergone some form of training in health economics
[4]. Third, our respondents were exposed to relevant
training in health management, and, to a lesser extent,
in health economics. It is important to stress that this
exposure is not comparable to occasional seminars or
attendance at sessions in conferences. Our respondents
committed themselves to about 35 days of demanding
class work and had the opportunity to enter the largest
Italian network on health-care management. In the
Euromet survey, a majority of respondents had only a
poor knowledge of basic economic evaluation tech-
niques, presumably because of the lack of comprehen-
sive training [4].
Obviously, we do not expect that our respondents
represent an unbiased sample of Italian medical doc-
tors, health managers or, more generally, decision
makers. This is a sample of informants, that is, medical
doctors who are likely to play relevant roles in the Ital-
ian health-care system and who should fully under-
stand the content and the jargon used in economic
evaluation studies.
We opted for this approach for two main reasons.
First, to survey an unbiased sample of health-care
decision-makers would have been very difﬁcult
because of problems in deﬁning the population of
decision-makers, in selecting and contacting an appro-
priate sample, and in motivating sampled individuals
Figure 1 Clinical areas for which economic evaluation analysis provides most beneﬁts.
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Figure 2 Level of decision-making for which economic evaluation analysis provides most beneﬁts. *P = 0.005 (chi-square).
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Figure 3 Frequency of consultations of economic evaluation studies in the year before survey.
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to respond; in fact, none of the surveys conducted in
Europe on the use of economic evaluation can so far
claim to have a reasonable picture of the large variety
of decision-makers in health care. More important,
surveying on such an issue is subject to the serious
threat that respondents do not fully understand the jar-
gon or the meaning of some questions, as suggested in
some of the European studies [4]. In this survey, we are
relatively conﬁdent that respondents had sufﬁcient
basic knowledge to fully understand the concepts and
the questions we have formulated.
To a certain extent, our results are consistent with
those obtained by Euromet [4,13] and other surveys
conducted in Europe [5,6]. All interviewees in the
Euromet survey considered an expertise in health eco-
nomics a desirable criterion when selecting their staff
whereas our respondents indicated health economics
and economic evaluation as being necessary for work-
ing in the health-care ﬁeld. Furthermore, Italian
respondents agreed with their European colleagues on
the role that training should play. Insufﬁcient health
economics training was cited by ﬁve out of six clinics
and eight out of 13 hospitals surveyed in France [5]
and “more training in health economics” ranked sec-
ond among possible incentives indicated by Euromet
respondents [4]. Our results also conﬁrmed that
economic evaluation does not play a major role in
decision-making. In the Euromet survey, lass than one-
third of respondents stated that they had made deci-
sions on the basis of the results of health economic
studies [4]. In our research the use of health economic
studies for both clinical and managerial decisions
appears somewhat more widespread.
Our survey presents new evidence on the use of eco-
nomic evaluation in health care. In regard to major
barriers, nearly 70% of respondents indicated the
adoption of a short-term perspective in decision-
making and an excessive control over expenditure as
the two major barriers in the use of economic evalua-
tion. These issues were not openly raised in previous
European surveys, at least to our knowledge, and
show that short-term ﬁnancial constraint may conﬂict
with economic rationality and, at least to a certain
extent, to efﬁcacy criteria. Our results show, addition-
ally, that the relative importance of these factors is per-
ceived differently by the two professional proﬁles.
Signiﬁcantly, more managers than clinicians recognize
short-term ﬁnancial constraints as a major obstacle. It
appears that professionals holding managerial roles
are more aware of the drawbacks of expenditure con-
trol measures that limit their scope of action and that
impose short-sighted decisions.
In regard to factors facilitating the use of economic
evaluation, respondents stressed two major issues in
addition to training: guidelines and support to
decision-makers. Establishing guidelines would assure
more comparability and higher quality. This is mainly
an Italian issue as no ofﬁcial guidelines have been
released by government institutions so far. The high
number of respondents who mentioned the importance
of services to help decision makers should suggest
major reasons for reﬂection. Because of the training
that they attended, our respondents were aware that
economic evaluation studies are, and probably need to
be, sophisticated, that their full understanding requires
time and specialized expertise, and that decision mak-
ers are not in the position to undergo the entire process
required to link the study to context-speciﬁc decisions.
This result shows their awareness in this respect and
should be further investigated. A realistic approach to
the relation between studies and decisions should dis-
cuss how  to  bridge  them.  More  evidence  is  needed
to understand how decisions are taken and how new
knowledge on economic issues is gained and used. In
addition, to facilitate the use of economic studies, it
would be important to investigate the role of informa-
tion technologies (electronic databases and simulations
models to be used for speciﬁc decisions) and the poten-
tials of professionals acting as brokers between
researchers and decision-makers. Finally, a better
understanding of institutional and organizational
arrangements (content of responsibilities, ﬁnancial
incentives) is required to check that they are consistent
with economic rationality.
Despite a similar path of studies (medicine and
management) and a signiﬁcant exposure to economic
evaluation, surveyed individuals presented important
differences. Those identiﬁed as managers stated that
they use economic evaluation more frequently and are
more convinced of its usefulness. Instead, those who
are somehow involved in clinical activities report they
are less knowledgeable. This suggests that attitudes
toward economic evaluation depend on organizational
roles and job content. Those who are not involved in
clinical activities, and are thus away from individual
patients, have a more positive attitude toward the prin-
ciples and the techniques of economic evaluation.
Also, the detection of different perceptions about bar-
riers to and facilitating factors in the use of economic
evaluation in health care suggest that training and
other activities to support the diffusion of economic
evaluation should be differentiated according to the
roles and job content of the beneﬁciaries.
In addition to providing new general evidence, this
survey aimed at investigating the role of economic
evaluation at different decision-making levels. We
focused our attention on three levels: clinical, organi-
zational, and policy, because they clearly reﬂect three
tiers in terms of accountability systems, objectives,
tasks, and decisional tools within the health-care sys-
tem. In this respect, our survey produced two main
results. First, respondents reported that economic eval-
uation is mostly beneﬁcial at organizational level.
Professionals who work in NHS organizations are
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convinced that economic evaluation studies can have
an impact at the level at which they act. This result is
very encouraging because it shows that managers con-
sider economic evaluation as a management tool and
do not delegate economic rationality to the policy
level. In this respect, it is worth repeating that this
result comes from people who generally have a medical
background. Second, only few respondents think that
economic evaluation is beneﬁcial at the clinical level.
For our informants, economic evaluation does not
have a signiﬁcant role at clinical level, a position
consistent with that expressed by Weinstein [14].
Although few respondents appreciated the use of eco-
nomic evaluation at clinical level, it is important to
note that about one-third of respondents mentioned
that it can be beneﬁcial for the developing of guide-
lines. In other words, the economic evaluation can
have a role also at clinical level, provided that deci-
sions at the “patient’s bed" are supported by clinical
guidelines.
Overall, our survey provides a more optimistic pic-
ture than those offered by previous studies. Our sam-
ple does believe that economic evaluation is somehow
useful and should be part of the weaponry of decision
makers. It also suggests that the logic of economic
evaluation is used in their organizations. This is not
enough to assert with conﬁdence that economic
evaluation studies have a direct impact on decision-
making, although some impact is very likely. It some-
how suggests that economic evaluation is enlightening
decision-makers.
Source of ﬁnancial support: No funding was received for the
present research. 
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Appendix Questionnaire on the Use of Economic Evaluation in Italian Health Care
Age . . . . . . . . 
Gender:  M  F
In which Region do you work at the moment?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Which type of organization?
 Hospital Trust
 Local Health Authority
 Teaching Hospital
 Research Hospital
 Private Accredited
 Private Non Accredited
 Other (specify)
Position/Role:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Year of course attendance:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
What type of activity do you currently perform?
 mainly clinical
 mainly managerial
 mix of clinical-managerial
 other (specify)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1) The basics of economic evaluations in health care had been presented in the ﬁnal part of the “planning and
programming” course of Corgesan (mainly an introduction to cost-effectiveness analysis).
Do you think that those contents should be a mandatory part of the overall training of professionals working in
health care?
 Yes
 No
 I don’t know
2) How much are those contents useful at professional level, judging from your experience?
(express your judgment on the scale from 1 to 5)
1 2 3 4 5
(not useful) (very much useful)
3) Do you think that those contents are useful for understanding the logic of economic reasoning?
(express your judgment on the scale from 1 to 5)
1 2 3 4 5
(not at all) (very much)
4) Is economic analysis (comparison between costs and effectiveness of alternatives) considered in making clin-
ical decisions in your health-care organization (for example: choices regarding therapy, diagnostic tests)?
(express your judgment on the scale from 1 to 5)
1 2 3 4 5
(Not at all) (Yes, very much)
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5) Is economic analysis (comparison between costs and effectiveness of alternatives) considered when manage-
rial decisions are made (for example: introducing a new technology, expanding volume of care, launching pre-
vention campaigns)?
(express your judgment on the scale from 1 to 5)
1 2 3 4 5
(Not at all) (Yes, very much)
6) In your opinion, what are the main barriers to a wider use of economic evaluations to make decisions in
health care?
(choose no more than 3)
 Potentially useful studies are not accessible at the right moment
 Difﬁculties in moving resources from one sector to another
 Studies are not reliable because they are conducted or sponsored by vested interests
 Those who decide don’t have the necessary knowledge to use this type of studies
 Too much focus on expenditure control
 Decisions are taken according to a short-term perspective
 Lack of incentives to reward rational choices
7) In your opinion, which areas could mostly beneﬁt from economic evaluation studies?
(choose no more than 3)
 Prevention services (vaccination, screening, etc.)
 Diagnostic services
 Surgical interventions
 Pharmacological therapies
 Rehabilitation services
8) What factors might facilitate a wider use of economic evaluation in health care?
(choose no more than 3)
 More training in health economics
 More ﬂexibility in allocation of resources
 Easier access to studies
 Support to decision makers (accessible database, consultancy services, etc.)
 Establishing guidelines in order to assure quality and comparability of studies
9) In your opinion, at which level of decision making can economic evaluation provide most beneﬁts?
 Clinical decisions
 Organizational decisions
 Establishing guidelines
 Regional—national level decision making (for example: decisions regarding the basic health beneﬁt 
package)
10) How many times, approximately, have you consulted economic evaluation studies in the last year?
 never
 1-3 times
 more than 3 times
11) How would you grade your knowledge of economic evaluation in health care?
1 2 3 4 5
(poor) (excellent)
12) Finally, we would be grateful if you could provide us with some qualitative comments.
